drugset / Trial / NCT00617461
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gabapentin enacarbil | Small molecule | 1200 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 3600 mg | Oral |